Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
,
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
Sept 8: At the end of July, Citius Pharmaceuticals received a Complete Response Letter from the FDA pertaining to its Biologics License Application for Lymphir, an engineered IL-2-diphtheria toxin fusion protein intended to treat relapsed or refractory cutaneous T-cell lymphoma
This D-retro-inverso peptide specifically disrupts the FOXO4-p53 protein interaction that maintains senescent cell viability, providing researchers with a sophisticated tool for investigating cellular senescence biology and its role in aging processes
At the core of neutrophil polarization lies the dynamic remodeling of cytoskeletal proteins
849 CAT improves intestinal I/R injury by activating the transient receptor potential cationic channel subfamily V member 1 (TRPV1), enhancing GPX4 expression, and inhibiting ferroptosis
US$ 25.10
US$ 23.72
US$ 24.09
US$ 28.76
US$ 22.42
